Sign up to save your podcasts
Or
Share #15 Francesca del Bufalo: CAR-T cells for neuroblastoma
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
#15 Francesca del Bufalo: CAR-T cells for neuroblastoma
Immunotherapy with chimeric antigen receptor (CAR)–expressing T cells
that target the disialoganglioside GD2 expressed on tumor cells may be a
therapeutic option for patients with high-risk neuroblastoma. In an
academic, phase 1–2 clinical trial, the investigators enrolled patients
(1 to 25 years of age) with relapsed or refractory, high-risk
neuroblastoma in order to test autologous, third-generation GD2-CAR T
cells expressing the inducible caspase 9 suicide gene (GD2-CART01).
https://www.nejm.org/doi/full/10.1056/NEJMoa2210859
ALSO AS VIDEO ON YOUTUBE
https://youtu.be/o1DVDcrrHFA
CONNECT WITH US
https://twitter.com/TheEBMT_Trainee
https://www.ebmt.org/trainee-committee
https://twitter.com/CarmeloGurnari
View all episodes
By The EBMT Trainee CommitteeImmunotherapy with chimeric antigen receptor (CAR)–expressing T cells
that target the disialoganglioside GD2 expressed on tumor cells may be a
therapeutic option for patients with high-risk neuroblastoma. In an
academic, phase 1–2 clinical trial, the investigators enrolled patients
(1 to 25 years of age) with relapsed or refractory, high-risk
neuroblastoma in order to test autologous, third-generation GD2-CAR T
cells expressing the inducible caspase 9 suicide gene (GD2-CART01).
https://www.nejm.org/doi/full/10.1056/NEJMoa2210859
ALSO AS VIDEO ON YOUTUBE
https://youtu.be/o1DVDcrrHFA
CONNECT WITH US
https://twitter.com/TheEBMT_Trainee
https://www.ebmt.org/trainee-committee
https://twitter.com/CarmeloGurnari